早期非小细胞肺癌:免疫检查点阻断剂和向治疗的新挑战
Pernelle Lavaud1, Martina Bortolot2,3, Lodovica Zullo1
1Gustave Roussy, Department of Cancer Medicine, Paris-Saclay University, 114, rue Edouard Vaillant, 94805 Villejuif, France.
Cancers
|August 29, 2024
概括
氨酸激酶抑制剂 (TKI) 和免疫检查点阻断剂 (ICB) 已经改变了早期非小细胞肺癌 (NSCLC) 治疗. 目前正在进行的研究解决了这些挑战,并探索了优化这些向治疗的生物标志物.
科学领域:
- 在瘤学瘤学.
- 胸部外科手术 胸部外科手术
- 药理学 药理学是指药理学的学科.
背景情况:
- 氨酸激酶抑制剂 (TKI) 和免疫检查点阻断剂 (ICB) 已经彻底改变了早期非小细胞肺癌 (NSCLC) 治疗.
- 针对性疗法,如奥西默蒂尼布 (EGFR突变) 和阿莱克提尼布 (ALK阳性) 在切除的NSCLC中改善了结果.
- 最近的数据,包括LAURA试验,强调了TKI在不可切除的III期NSCLC中的疗效,扩大了治疗范式.
研究的目的:
- 审查早期NSCLC中TKI和ICB的现有证据.
- 讨论正在进行的临床试验,研究新辅助/术后TKI和ICB疗法.
- 识别和解决用于NSCLC的TCI和ICB利用方面的挑战.
主要方法:
- 在早期NSCLC中对TKI和ICB应用的综合文献综述.
- 从关键试验 (如LAURA) 和正在进行的研究中分析数据.
- 讨论治疗挑战,包括最佳持续时间,最小残留疾病 (MRD) 的作用和生物标志物的发展.
主要成果:
- 已批准TKIs (osimertinib,alectinib) 和ICBs (atezolizumab,pembrolizumab,nivolumab) 用于各种早期NSCLC设置 (辅助,新辅助,外科手术期间).
- 在特定的患者亚组中,这些药物观察到预后的显著改善.
- 许多试验正在评估新的TKI和ICB策略,包括术后使用和组合.
结论:
- 技术知识和ICB代表了NSCLC早期管理的范式转变,提供了更好的结果.
- 关键的挑战仍然存在,包括定义最佳治疗持续时间,整合MRD评估和确定预测生物标志物.
- 进一步的研究对于完善基于TKI和ICB的策略至关重要,以最大限度地提高早期NSCLC的疗效.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:27Tumor Immunotherapy
493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K